Handling covariates in the design of clinical trials WF Rosenberger, O Sverdlov Statistical Science 23 (3), 404-419, 2008 | 193 | 2008 |
Digital therapeutics: an integral component of digital innovation in drug development O Sverdlov, J Van Dam, K Hannesdottir, T Thornton‐Wells Clinical Pharmacology & Therapeutics 104 (1), 72-80, 2018 | 156 | 2018 |
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile … G Tong, JS Wang, O Sverdlov, SP Huang, R Slemmon, R Croop, ... Clinical therapeutics 34 (3), 654-667, 2012 | 92 | 2012 |
Adaptive randomization for clinical trials WF Rosenberger, O Sverdlov, F Hu Journal of biopharmaceutical statistics 22 (4), 719-736, 2012 | 81 | 2012 |
Pharmacodynamics of selective inhibition of γ-secretase by avagacestat CF Albright, RC Dockens, JE Meredith, RE Olson, R Slemmon, KA Lentz, ... Journal of Pharmacology and Experimental Therapeutics 344 (3), 686-695, 2013 | 78 | 2013 |
A roadmap to using randomization in clinical trials VW Berger, LJ Bour, K Carter, JJ Chipman, CC Everett, N Heussen, ... BMC medical research methodology 21, 1-24, 2021 | 55 | 2021 |
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects R Dockens, JS Wang, L Castaneda, O Sverdlov, SP Huang, R Slemmon, ... Clinical pharmacokinetics 51, 681-693, 2012 | 55 | 2012 |
Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men G Tong, L Castaneda, JS Wang, O Sverdlov, SP Huang, R Slemmon, ... Clinical drug investigation 32, 761-769, 2012 | 47 | 2012 |
Modern adaptive randomized clinical trials: statistical and practical aspects O Sverdlov CRC Press, 2015 | 46 | 2015 |
On recent advances in optimal allocation designs in clinical trials O Sverdlov, WF Rosenberger Journal of Statistical Theory and Practice 7, 753-773, 2013 | 44 | 2013 |
Optimal response‐adaptive randomized designs for multi‐armed survival trials O Sverdlov, Y Tymofyeyev, WK Wong Statistics in medicine 30 (24), 2890-2910, 2011 | 44 | 2011 |
Adaptive clinical trial designs for phase I cancer studies O Sverdlov, WK Wong, Y Ryeznik | 33 | 2014 |
Utility of covariate-adjusted response-adaptive randomization in survival trials O Sverdlov, WF Rosenberger, Y Ryeznik Statistics in Biopharmaceutical Research 5 (1), 38-53, 2013 | 28 | 2013 |
An overview of healthcare data analytics with applications to the COVID-19 pandemic Z Fei, Y Ryeznik, O Sverdlov, CW Tan, WK Wong IEEE Transactions on Big Data 8 (6), 1463-1480, 2021 | 24 | 2021 |
A comparative study of restricted randomization procedures for multiarm trials with equal or unequal treatment allocation ratios Y Ryeznik, O Sverdlov Statistics in Medicine 37 (21), 3056-3077, 2018 | 24 | 2018 |
A study of novel exploratory tools, digital technologies, and central nervous system biomarkers to characterize unipolar depression O Sverdlov, J Curcic, K Hannesdottir, L Gou, V De Luca, F Ambrosetti, ... Frontiers in Psychiatry 12, 640741, 2021 | 23 | 2021 |
Citalopram for acute and preventive efficacy in bipolar depression (CAPE-BD): a randomized, double-blind, placebo-controlled trial SN Ghaemi, EA Whitham, PA Vohringer, SA Barroilhet, A Amerio, ... The Journal of Clinical Psychiatry 82 (1), 6067, 2021 | 22 | 2021 |
A smartphone-based intervention as an adjunct to standard-of-care treatment for schizophrenia: randomized controlled trial SN Ghaemi, O Sverdlov, J van Dam, T Campellone, R Gerwien JMIR formative research 6 (3), e29154, 2022 | 21 | 2022 |
Implementing unequal randomization in clinical trials with heterogeneous treatment costs O Sverdlov, Y Ryeznik Statistics in Medicine 38 (16), 2905-2927, 2019 | 21 | 2019 |
Randomization in clinical trials: can we eliminate bias? O Sverdlov, WF Rosenberger | 20 | 2013 |